1. Home
  2. HURA vs LCNB Comparison

HURA vs LCNB Comparison

Compare HURA & LCNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • LCNB
  • Stock Information
  • Founded
  • HURA 2009
  • LCNB 1877
  • Country
  • HURA United States
  • LCNB United States
  • Employees
  • HURA N/A
  • LCNB N/A
  • Industry
  • HURA
  • LCNB Major Banks
  • Sector
  • HURA
  • LCNB Finance
  • Exchange
  • HURA Nasdaq
  • LCNB Nasdaq
  • Market Cap
  • HURA 193.8M
  • LCNB 212.3M
  • IPO Year
  • HURA N/A
  • LCNB N/A
  • Fundamental
  • Price
  • HURA $3.35
  • LCNB $16.89
  • Analyst Decision
  • HURA
  • LCNB
  • Analyst Count
  • HURA 0
  • LCNB 0
  • Target Price
  • HURA N/A
  • LCNB N/A
  • AVG Volume (30 Days)
  • HURA 77.7K
  • LCNB 22.3K
  • Earning Date
  • HURA 11-14-2024
  • LCNB 10-21-2024
  • Dividend Yield
  • HURA N/A
  • LCNB 5.13%
  • EPS Growth
  • HURA N/A
  • LCNB N/A
  • EPS
  • HURA N/A
  • LCNB 0.52
  • Revenue
  • HURA N/A
  • LCNB $74,686,000.00
  • Revenue This Year
  • HURA N/A
  • LCNB N/A
  • Revenue Next Year
  • HURA N/A
  • LCNB $15.49
  • P/E Ratio
  • HURA N/A
  • LCNB $32.96
  • Revenue Growth
  • HURA N/A
  • LCNB 3.03
  • 52 Week Low
  • HURA $2.84
  • LCNB $12.42
  • 52 Week High
  • HURA $17.36
  • LCNB $17.27
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • LCNB 62.34
  • Support Level
  • HURA N/A
  • LCNB $16.56
  • Resistance Level
  • HURA N/A
  • LCNB $17.04
  • Average True Range (ATR)
  • HURA 0.00
  • LCNB 0.34
  • MACD
  • HURA 0.00
  • LCNB -0.01
  • Stochastic Oscillator
  • HURA 0.00
  • LCNB 71.21

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About LCNB LCNB Corporation

LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.

Share on Social Networks: